SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
SCYNEXIS Inc SCYX
$4.39
▼ -1.35%
($-0.06)
⬇️ Below Yest. Low
Open
$4.58
Prev Close
$4.45
Day Range
$4.37 – $4.58
52W Range
$3.53 – $9.12
Market Cap
$43.68M
Beta
1.13
EPS (TTM)
$-2.16
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-05-02 |
| Shares Out. | 9,930,000 |
| Website | scynexis.com/ ↗ |
| Phone | 12018845485 |
| Employees | 29 |
| Revenue | $235,000 |
| Gross Profit | $235,000 |
| Net Income | $7.4M |
| Free Cash Flow | -$13.3M |
| Total Assets | $75.0M |
| Total Liabilities | $8.0M |
| Equity | $66.9M |
About SCYNEXIS Inc
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
SCYNEXIS Inc is a publicly traded company under the ticker symbol SCYX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)